We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+24.32%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$831M
AUM Growth
-$107M
Cap. Flow
-$210M
Cap. Flow %
-25.25%
Top 10 Hldgs %
81.97%
Holding
43
New
8
Increased
4
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$87.3M
2
GMED icon
Globus Medical
GMED
+$36M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$31M
4
LEGN icon
Legend Biotech
LEGN
+$25.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$24.3M

Top Sells

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$78.7M
2
UTHR icon
United Therapeutics
UTHR
+$76M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$43.7M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.6M
5
ARVN icon
Arvinas
ARVN
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.32%
2 Financials 1.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARYD
26
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$2.68M 0.32%
250,000
– –
TNGX icon
27
Tango Therapeutics
TNGX
$4.85B
$2.05M 0.25%
180,000
– –
PANA
28
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$2M 0.24%
+200,000
New +$2M
TKNO icon
29
Alpha Teknova
TKNO
$296M
$1.78M 0.21%
+75,000
New +$1.9M
MLTX icon
30
MoonLake Immunotherapeutics
MLTX
$1.52B
$1.55M 0.19%
150,000
– –
CMAXW
31
DELISTED
CareMax, Inc. Warrant
CMAXW
$217K 0.03%
+45,960
New +$188K
MSACW
32
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$34K ﹤0.01%
+33,331
New +$26.4K
ARVN icon
33
Arvinas
ARVN
$555M
– –
-460,000
Closed -$30.4M
ATRA icon
34
Atara Biotherapeutics
ATRA
$79.2M
– –
-66,772
Closed -$24M
IOVA icon
35
Iovance Biotherapeutics
IOVA
$1.96B
– –
-790,197
Closed -$25M
MGNX icon
36
MacroGenics
MGNX
$250M
– –
-2,472,447
Closed -$78.7M
STXS icon
37
Stereotaxis
STXS
$139M
– –
-3,508,676
Closed -$23.6M
IMGN
38
DELISTED
Immunogen Inc
IMGN
– –
-703,790
Closed -$5.7M
MRTX
39
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-255,203
Closed -$43.7M
TPTX
40
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-450,396
Closed -$42.6M
DFHTU
41
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
– –
-229,800
Closed -$3.01M
MSACU
42
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
– –
-300,000
Closed -$2.96M
CTIC
43
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-2,512,800
Closed -$7.31M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Consonance Capital Management held 43 positions worth $831M, down 11% from $938M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Consonance Capital Management withdrew a net $210M in Q2 2021, closing 11 positions and reducing 13 holdings. Its most notable exit was MacroGenics, an estimated $78.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Financials.

Against the trend, Consonance Capital Management opened a new position in Tandem Diabetes Care worth $95.4M.

  • Consonance Capital Management's largest Q2 2021 buy was Tandem Diabetes Care: 979,226 shares worth $95.4M.
  • Consonance Capital Management added most to Globus Medical in Q2 2021, an estimated $36M increase.
  • Consonance Capital Management's biggest Q2 2021 reduction was United Therapeutics, cutting an estimated $76M.
  • Consonance Capital Management fully exited MacroGenics in Q2 2021, selling an estimated $78.7M.
  • Consonance Capital Management's ten largest holdings make up 82% of its $831M portfolio in Q2 2021.
  • Consonance Capital Management opened 8 new positions and closed 11 in Q2 2021.
  • Consonance Capital Management's portfolio value fell 11% quarter-over-quarter to $831M.

Based on Consonance Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.